ClinicalTrials.gg
CompletedNCT04347525Updated Nov 8, 2022

The Effect of Culturally Adapted CBT-based Guided Self Help in Depressed Patients With Myocardial Infarction

An interventional study of CaCBT based guided self help using Khushi aur Khatoon Manual in Myocardial Infarction and Depression, sponsored by Peshawar Medical College. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Peshawar Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Oct 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Myocardial Infarction with a site in Pakistan — 3 open to participants now, 5 under way, none of them phase 3. Myocardial Infarction · Pakistan.

Enrollment
7th of 16
140 · median 77
Started
2019
the only one that year
No phase
9 of 17
2 open now
Registered
6th of 17
by date
Lead sponsor
1 of 17
Peshawar Medical College

Among the 17 studies in Myocardial Infarction with a site in Pakistan, this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2019, is one of 9 with no phase, and was the 6th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

3 of the 17 studies in Myocardial Infarction with a site in Pakistan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myocardial Infarction with a site in Pakistan, or all of them as a file.
02

Study summary

This is a randomized controlled assessor-blind clinical trial comparing CaCBT based guided self-help (using a manual titled Khushi Aur Khatoon) against treatment as usual (TAU)

Read the detailed description

Among patients with heart disease, depression and anxiety disorders are extremely common. After a myocardial infarction (MI), depression tends to persist over the next year. Similarly, among individuals who have significantly elevated anxiety following an episode of acute coronary syndrome, only 50% have a resolution of their anxiety in the year after the event, which suggests that anxiety can remain a chronic problem for many patients. Depression confers a 2-fold increased risk of mortality and adverse cardiac events after MI or heart failure and has been linked to poor outcomes after cardiac surgery.

Cognitive behavioural therapy (CaCBT) is the best-studied form of psychotherapy in patients who have had a myocardial infarction, in reducing depressive symptoms. However, there is a dearth of literature on the use of psycho-social interventions in those with medical problems in low and middle-income countries. This study is planned to explore the effect of culturally adapted Cognitive Behavioural Therapy (CaCBT) based Guided self-help (using the book, Khushi Aur Khatoon) compared with treatment as usual in improving depression in MI patients. Participants visiting the Punjab Institute of Cardiology - Lahore, who meet the entry criteria will be randomly allocated to one of the groups, i.e., CaCBT (Intervention group) or TAU (Control Group) in a 1:1 ratio. after taking written informed consent.

With a 5% significance level and 90% power, it was calculated that 48 subjects per group were required for the trial, with a total number of 96. To accommodate up to 30% of the dropout, the participants plan to recruit 140 participants in the study.

Participants were assessed at baseline and 9-12 weeks (end of therapy) from baseline. The primary outcome measure was the Hospital Anxiety and Depression Scale (HADS). The secondary outcome measures include HADS Anxiety and Depression Subscales; Bradford Somatic Inventory (BSI) and World Health Organization Disability Assessment Schedule (WHO DAS 2.0). The participants also measured satisfaction with the treatment at the end of therapy using a visual analog scale.

The participants followed the CONSORT guidelines for reporting randomized controlled trials. The analyses were carried out on an intention-to-treat basis using SPSS version 25. Comparisons for intention-to-treat analysis participants were included in the groups to which they are randomized regardless of how long or even whether they received the treatment allocated to them or not. Missing values were imputed using the last observation carried forward (LOCF) method. Both Chi-Square and t-tests were used for baseline comparisons. End-of-therapy scores on various outcome measures between the Intervention and the Control groups were compared using an Analysis of Covariance (ANCOVA) to adjust for baseline scores.

03

Conditions studied

  • Myocardial Infarction
  • Depression

Keywords

  • Cognitive Behaviour Therapy
  • Depression
  • Myocardial Infarction
  • Guided Self Help
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Myocardial Infarction
  • Score 8 or more on HADS
  • Fulfilling criteria of Major Depressive Disorder using

Exclusion criteria

Exclusion Criteria:

  • Participants with use of alcohol or drugs
  • Significant cognitive impairment (intellectual disability or dementia)
  • Active psychosis
  • Participants who have received CBT during the previous 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Intervention

    This group will receive CaCBT based guided self-help using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual

    Other: CaCBT based guided self help using Khushi aur Khatoon Manual

  • No intervention
    Control

    This group will receive treatment as usual

Interventions

  • OtherCaCBT based guided self help using Khushi aur Khatoon Manual

    CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm

06

What researchers measure

Primary outcomes

  1. Hospital Anxiety and Depression Scale-Depression Subscale (HAD-D)

    Change in the score of the Hospital Anxiety and Depression Scale (HADS) from baseline to end of therapy. The total score is the sum of the 7 items, ranging from 0-21. A total subscale score of \>8 points out of a possible 21 denotes considerable symptoms of depression.

    Time frame: 9-12 weeks (end of therapy)

Secondary outcomes

  1. Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)

    Change in the score of the Hospital Anxiety and Depression Scale, Anxiety subscale (HADS-A) from baseline to end of therapy. The total score is the sum of the 7 items, ranging from 0-21. A total subscale score of \>8 points out of a possible 21 denotes considerable symptoms of anxiety.

    Time frame: 9-12 weeks (end of therapy)

  2. Bradford Somatic Inventory (BSI)

    Change in the score of Bradford Somatic Inventory (BSI) from baseline to end of therapy. Respondents rank each feeling item on a 5-point scale ranging from 0 (not at all) to 4 (extremely). Rankings characterize the intensity of distress during the past 7 days. Scores can be summed for each dimension, or calculated into each global index.

    Time frame: 9-12 weeks (end of therapy)

  3. World Health Organisation Disability Assessment Schedule (WHODAS 2.0)

    Change in the score of World Health Organisation Disability Assessment Schedule (WHODAS 2.0) from baseline to end of therapy. The total score for WHODAS ranges from 0-100, where a high score indicates major living limitations.

    Time frame: 9-12 weeks (end of therapy)

07

Study locations

1 site
  • Punjab Institute of Cardiology
    Lahore, Punjab, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Mar 2020, 4 months.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's 4 months is below that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2020
First posted
Apr 15, 2020
StartActual
Oct 22, 2019
Primary completionActual
Mar 15, 2020
CompletionActual
Apr 25, 2020
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04347525
Lead sponsor
Peshawar Medical College
Collaborators
Pakistan Association of Cognitive Therapists
Responsible party
Muhammad Irfan (Prof of Psychiatry & Director Research, Peshawar Medical College) — Principal investigator
First posted
Apr 15, 2020
Start date
Oct 22, 2019
Primary completion
Mar 15, 2020
Completion
Apr 25, 2020
Last update
Nov 8, 2022

Study contacts

Farooq Naeem, PhD
study chair · University of Toronto

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion